|
|
VANCOUVER, BC / ACCESSWIRE / February 14, 2024 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", a leading biopharma company in psychiatric medicine development, is delighted to announce the completion of its landmark Phase 2a clinical trial in patients with Major Depressive Disorder.MindBio has achieved a significant milestone becoming the only... Lire le communiqué |
|
| |
|
| |
|
|
VANCOUVER, BC / ACCESSWIRE / January 30, 2024 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", announces it is nearing the completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder.MindBio is pleased to report that dosing is progressing well in its Phase 2a Depression trial using MB22001 MindBios... Lire le communiqué |
|
| |
|
| |
|
|
VANCOUVER, BC / ACCESSWIRE / December 20, 2023 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", Chief Executive Officer Justin Hanka provides end of year video update on two Phase 2 clinical trials currently underway using MB22001.... Lire le communiqué |
|
| |
|
| |
|
|
VANCOUVER, BC / ACCESSWIRE / November 21, 2023 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", is pleased to report two of its team members have been honoured with industry leading awards.... Lire le communiqué |
|
| |
|
| |
|
|
World first approved for take home in cancer patients experiencing emotional distressMB22001 is a proprietary titratable form of LSD Lysergic Acid Diethylamide for convenient takehome MicrodosingOne of two Phase 2 trials currently underway:Phase 2A LSDMicrodosing MB22001 in patients with Major Depressive Disorder, and;Phase 2B LSDM... Lire le communiqué |
|
| |
|
| |
|
|
World first take home trials in cancer patients experiencing emotional distressFirst doses in patients have been administeredA Phase 2B clinical trial assessing the effectiveness of psychedelic LSD MB22001 Microdosing with Meaning Centred Psychotherapy in advanced stage cancer patientsOne of two Phase 2 trials currently underwayVANCOUV... Lire le communiqué |
|
| |
|
| |
|
|
VANCOUVER, BC / ACCESSWIRE / October 26, 2023 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", is pleased to report the Company has been nominated for Company of the Year as well as other profile awards, at the upcoming industry awards Wonderland, presented by Microdose to be held in Miami in November. Last year, MindBio and its Chief Executive... Lire le communiqué |
|
| |
|
| |
